Please login to the form below

Not currently logged in
Email:
Password:

Clovis Oncology

This page shows the latest Clovis Oncology news and features for those working in and with pharma, biotech and healthcare.

ViiV’s two-drug HIV combo backed by CHMP

ViiV’s two-drug HIV combo backed by CHMP

It also gave its blessing to Clovis Oncology’s PARP inhibitor Rubraca (rucaparib) for the treatment of relapsed or progressive ovarian cancer in patients who have already been treated with two

Latest news

  • CHMP backs AZ’s Lynparza for ovarian cancer maintenance CHMP backs AZ’s Lynparza for ovarian cancer maintenance

    in the face of competition from newer market entrants Rubraca (rucaparib) from Clovis Oncology and Johnson &Johnson/Tesaro’s Zejula (niraparib). ... Tesaro and Clovis will report fourth quarter results this week.

  • AZ and Merck & Co get FDA breast cancer nod for Lynparza AZ and Merck & Co get FDA breast cancer nod for Lynparza

    Approval beyond ovarian cancer is a big hurdle cleared for Lynparza as it tries to keep pace in the market with newer PARP inhibitor entrants Rubraca (rucaparib) from Clovis Oncology and ... Merck (known as MSD outside the US and Canada) got involved in

  • CHMP backs maintenance therapy for Tesaro's Zejula CHMP backs maintenance therapy for Tesaro's Zejula

    Swiss biotech Tesaro has picked up a CHMP recommendation for its PARP inhibitor Zejula as a maintenance therapy for ovarian cancer, upping the ante in its rivalry with AstraZeneca and Clovis ... Oncology. The EMA's advisory committee backed Zejula

  • Lynparza approval sets up tighter bout with PARP rivals Lynparza approval sets up tighter bout with PARP rivals

    Another PARP inhibitor - Clovis Oncology's Rubraca (rucaparib) - was approved last December for use in women with advanced ovarian cancer who have been treated with two or more chemotherapies and have ... since it reported disappointing results with its

  • BMS and Clovis join forces in PARP combo race BMS and Clovis join forces in PARP combo race

    BMS and Clovis join forces in PARP combo race. Duo will combine Opdivo and Rubraca in phase II and III trials to treat a variety of tumours. ... The promise of combining PARP inhibitors and checkpoint inhibitors in cancer is exciting oncologists, and

More from news
Approximately 4 fully matching, plus 18 partially matching documents found.

Latest appointments

  • Roche's Julie Warner joins Boyds Roche's Julie Warner joins Boyds

    She has previously held positions at Clovis Oncology UK, Genzyme and Gregory Fryer Associate, and was most recently senior regulatory programme manager at Roche.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics